Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression
| Autor: | Leorey N. Saligan, Allison C. Nugent, Nada Lukkahati, Mark J. Niciu, Rodrigo Machado-Vieira, Carlos A. Zarate, Robin Ortiz, David A. Luckenbaugh |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder N-Methylaspartate Hippocampus Receptors N-Methyl-D-Aspartate Amygdala Article Double-Blind Method Internal medicine Humans Medicine Ketamine Bipolar disorder Receptor Aged business.industry medicine.disease Antidepressive Agents Pathophysiology Psychiatry and Mental health Clinical Psychology Treatment Outcome Endocrinology medicine.anatomical_structure Anesthesia NMDA receptor Antidepressant Female business Biomarkers medicine.drug |
| Zdroj: | Journal of Affective Disorders. 172:307-311 |
| ISSN: | 0165-0327 |
| DOI: | 10.1016/j.jad.2014.09.015 |
| Popis: | Background Shank3, a post-synaptic density protein involved in N-methyl- d -aspartate (NMDA) receptor tethering and dendritic spine rearrangement, is implicated in the pathophysiology of bipolar disorder. We hypothesized that elevated baseline plasma Shank3 levels might predict antidepressant response to the NMDA receptor antagonist ketamine. Methods Twenty-nine subjects with bipolar depression received a double-blind, randomized, subanesthetic dose (.5 mg/kg) ketamine infusion. Of the patients for whom Shank3 levels were collected, 15 completed baseline 3-Tesla MRI and 17 completed post-ketamine [ 18 F]-FDG PET. Results Higher baseline Shank3 levels predicted antidepressant response at Days 1 ( r =−.39, p =.047), 2 ( r =−.45, p =.02), and 3 ( r =−.42, p =.03) and were associated with larger average ( r =.58, p =.02) and right amygdala volume ( r =.65, p =.009). Greater baseline Shank3 also predicted increased glucose metabolism in the hippocampus ( r =.51, p =.04) and amygdala ( r =.58, p =.02). Limitations Limitations include the small sample size, inability to assess the source of peripheral Shank3, and the lack of a placebo group for baseline Shank3 levels and comparative structural/functional neuroimaging. Conclusions Shank3 is a potential biomarker of antidepressant response to ketamine that correlates with baseline amygdala volume and increased glucose metabolism in the amygdala and hippocampus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect